Do thallium myocardial perfusion scan abnormalities predict survival in sarcoid patients without cardiac symptoms?
Whereas the total mortality rate for sarcoidosis is 0.2 per 100,000, the prognosis, when the heart is involved, is very much worse. The authors used the difference in mortality rate to infer whether thallium 201 myocardial perfusion scan abnormalities correspond to myocardial sarcoid by making the simplifying assumption that if they do, then patients with abnormal scans will be found to have a death rate similar to patients with sarcoid heart disease. The authors therefore analyzed complete survival data on 52 sarcoid patients without cardiac symptoms an average of eighty-nine months after they had been scanned as part of a protocol. By use of survival analysis (the Cox proportional hazards model), the only variable that was significantly associated with survival was age. The patients' scan pattern, treatment status, gender, and race were not significantly related to survival. The authors conclude that thallium myocardial perfusion scans cannot reliably be used to diagnose sarcoid heart disease in sarcoid patients without cardiac symptoms.
Kinney
E L
EL
Reed Institute, Miami, Florida.
Caldwell
J W
JW
D000328:Adult; D000367:Age Factors; D009202:Cardiomyopathies / Q000000981:diagnostic imaging* / Q000401:mortality; D005260:Female; D006321:Heart / Q000000981:diagnostic imaging*; D006801:Humans; D008297:Male; D008875:Middle Aged; D011379:Prognosis; D011877:Radionuclide Imaging; D012507:Sarcoidosis / Q000000981:diagnostic imaging / Q000401:mortality*; D013534:Survival; D013794:Thallium Radioisotopes
D013794:Thallium Radioisotopes